Acalabrutinib

Drug Profile

Acalabrutinib

Alternative Names: ACP-196

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Acerta Pharma
  • Developer Acerta Pharma; Merck Sharp & Dohme; University Hospital Southampton NHS Foundation Trust
  • Class Antineoplastics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase II Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis
  • Phase I/II B cell lymphoma; B cell prolymphocytic leukaemia; Diffuse large B cell lymphoma; Glioblastoma; Waldenstrom's macroglobulinaemia
  • Phase I Follicular lymphoma; Multiple myeloma

Most Recent Events

  • 16 May 2017 Phase-III clinical trials in Mantle cell lymphoma (Combination therapy, First-line therapy, In the elderly) in Hungary (PO) (EudraCT2015-005220-26)
  • 01 Apr 2017 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in United Kingdom (PO) (ISRCTN13626902)
  • 09 Mar 2017 University Hospital Southampton NHS Foundation Trust plans the ACCEPT phase I/II trial for Diffuse large B-cell lymphoma in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top